Pfizer Secures $1.5B Deal for Obesity Drug
Pfizer secures up to $1.5 billion in development funding from Blackstone Life…
Wegovy Pill Sales Drive Stronger 2026 Outlook
Novo Nordisk raises its 2026 financial outlook for the third time as…
Clinical Study Explores Precision Nutrition to Support Patients on GLP-1 Therapy
M42’s IROS and 10XREVIV launch a clinical study to assess how precision…
Bahrain Approves Oral Wegovy for Obesity Treatment
Bahrain approves oral Wegovy (semaglutide) for obesity treatment, becoming the second GCC…
WHO Advises Against Obesity Medicines for Children Under 10
WHO advises against obesity medicines and GLP-1 weight-loss injections for children under…
UAE Becomes a Global Testing Ground for the Weight Loss Pill Everyone’s Talking About
The UAE has become the second country globally to approve oral Wegovy…
Novo Nordisk Collaborates with Vivani Medical to Evaluate Long-Acting Semaglutide Implant
A new collaboration will evaluate a long-acting semaglutide implant for chronic weight…
UAE Report Obesity Intervention contributes $51 billion to the country’s GDP by 2031
A new UAE report launched in collaboration with the Ministry of Economy…
Antag Therapeutics appoints obesity treatment pioneer Philip Just Larsen as Chief Executive Officer
Antag Therapeutics has appointed obesity treatment expert Philip Just Larsen as Chief…
UAE Among First Globally to Approve New Obesity and Hypertension Treatments
The United Arab Emirates is strengthening its global leadership in healthcare innovation…
